Institut für Mikrobiologie und Hygiene, Charité-Universitätsmedizin Berlin, Berlin, Germany.
PLoS One. 2010 Dec 3;5(12):e15099. doi: 10.1371/journal.pone.0015099.
The health beneficial effects of Resveratrol, Curcumin and Simvastatin have been demonstrated in various experimental models of inflammation. We investigated the potential anti-inflammatory and immunomodulatory mechanisms of the above mentioned compounds in a murine model of hyper-acute Th1-type ileitis following peroral infection with Toxoplasma gondii.
METHODOLOGY/PRINCIPAL FINDINGS: Here we show that after peroral administration of Resveratrol, Curcumin or Simvastatin, mice were protected from ileitis development and survived the acute phase of inflammation whereas all Placebo treated controls died. In particular, Resveratrol treatment resulted in longer-term survival. Resveratrol, Curcumin or Simvastatin treated animals displayed significantly increased numbers of regulatory T cells and augmented intestinal epithelial cell proliferation/regeneration in the ileum mucosa compared to placebo control animals. In contrast, mucosal T lymphocyte and neutrophilic granulocyte numbers in treated mice were reduced. In addition, levels of the anti-inflammatory cytokine IL-10 in ileum, mesenteric lymph nodes and spleen were increased whereas pro-inflammatory cytokine expression (IL-23p19, IFN-γ, TNF-α, IL-6, MCP-1) was found to be significantly lower in the ileum of treated animals as compared to Placebo controls. Furthermore, treated animals displayed not only fewer pro-inflammatory enterobacteria and enterococci but also higher anti-inflammatory lactobacilli and bifidobacteria loads. Most importantly, treatment with all three compounds preserved intestinal barrier functions as indicated by reduced bacterial translocation rates into spleen, liver, kidney and blood.
CONCLUSION/SIGNIFICANCE: Oral treatment with Resveratrol, Curcumin or Simvastatin ameliorates acute small intestinal inflammation by down-regulating Th1-type immune responses and prevents bacterial translocation by maintaining gut barrier function. These findings provide novel and potential prophylaxis and treatment options of patients with inflammatory bowel diseases.
白藜芦醇、姜黄素和辛伐他汀的有益健康的效果已在各种炎症的实验模型中得到证实。我们研究了上述化合物在经口感染弓形虫后发生的超急性 Th1 型回肠炎的小鼠模型中潜在的抗炎和免疫调节机制。
方法/主要发现:在这里,我们表明,在给予白藜芦醇、姜黄素或辛伐他汀口服后,小鼠免受回肠炎的发展,并在炎症的急性期存活下来,而所有安慰剂治疗的对照组都死亡了。特别是,白藜芦醇治疗导致了更长时间的存活。与安慰剂对照组相比,白藜芦醇、姜黄素或辛伐他汀治疗的动物显示出调节性 T 细胞数量显著增加,并增强了回肠黏膜上皮细胞的增殖/再生。相比之下,治疗组的黏膜 T 淋巴细胞和嗜中性粒细胞数量减少。此外,回肠、肠系膜淋巴结和脾脏中的抗炎细胞因子 IL-10 水平增加,而治疗动物的回肠中促炎细胞因子表达(IL-23p19、IFN-γ、TNF-α、IL-6、MCP-1)则显著降低。此外,治疗组不仅表现出较少的促炎肠杆菌和肠球菌,而且具有更高的抗炎乳杆菌和双歧杆菌负荷。最重要的是,所有三种化合物的治疗均保留了肠道屏障功能,这表明细菌易位进入脾、肝、肾和血液的速率降低。
结论/意义:白藜芦醇、姜黄素或辛伐他汀的口服治疗通过下调 Th1 型免疫反应来改善急性小肠炎症,并通过维持肠道屏障功能来防止细菌易位。这些发现为炎症性肠病患者提供了新的潜在预防和治疗选择。